InsiderTrades.com logo
Secret Bull Market Starts in This Unusual Sector
From Altimetry   |   Ad
"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.
Click for my No. 1 investment, all free of charge, click here. 
Shoshana Shendelman net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Shoshana Shendelman Biography and Net Worth

CEO of Applied Therapeutics

Shoshana Shendelman, PhD founded Applied Therapeutics in 2016. She serves as President and Chief Executive Officer as well as Chair of the Board of Directors. Prior to founding Applied Therapeutics, she founded Clearpoint Strategy Group LLC, a boutique life sciences consulting firm, where she served as the Managing Director from July 2012 to December 2016 and served as a Senior Advisor from January 2017 to December 2018. Dr. Shendelman received her Ph.D. in Cellular, Molecular and Biophysical Studies (CMBS) from Columbia University Vagelos College of Physicians and Surgeons.

Dr. Shendelman is a member of the Clinical Advisory Board of Columbia University Medical Center and Columbia University Vagelos College of Physicians & Surgeons, where she serves on the Nominations Committee and the Committee on Innovation and Entrepreneurship.

What is Shoshana Shendelman's net worth?

The estimated net worth of Shoshana Shendelman is at least $16.72 million as of March 14th, 2024. Dr. Shendelman owns 3,817,814 shares of Applied Therapeutics stock worth more than $16,722,025 as of April 20th. This net worth evaluation does not reflect any other investments that Dr. Shendelman may own. Additionally, Dr. Shendelman receives an annual salary of $813,470.00 as CEO at Applied Therapeutics. Learn More about Shoshana Shendelman's net worth.

How old is Shoshana Shendelman?

Dr. Shendelman is currently 45 years old. There are 5 older executives and no younger executives at Applied Therapeutics. The oldest executive at Applied Therapeutics is Dr. Riccardo Perfetti M.D., Ph.D., Chief Medical Officer, who is 63 years old. Learn More on Shoshana Shendelman's age.

What is Shoshana Shendelman's salary?

As the CEO of Applied Therapeutics, Inc., Dr. Shendelman earns $813,470.00 per year. The highest earning executive at Applied Therapeutics is Dr. Riccardo Perfetti M.D., Ph.D., Chief Medical Officer, who commands a salary of $858,000.00 per year. Learn More on Shoshana Shendelman's salary.

How do I contact Shoshana Shendelman?

The corporate mailing address for Dr. Shendelman and other Applied Therapeutics executives is 340 MADISON AVENUE 19TH FLOOR, NEW YORK NY, 10173. Applied Therapeutics can also be reached via phone at (212) 220-9226 and via email at [email protected]. Learn More on Shoshana Shendelman's contact information.

Has Shoshana Shendelman been buying or selling shares of Applied Therapeutics?

Shoshana Shendelman has not been actively trading shares of Applied Therapeutics during the last ninety days. Most recently, Shoshana Shendelman sold 318,573 shares of the business's stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $5.39, for a transaction totalling $1,717,108.47. Following the completion of the sale, the chief executive officer now directly owns 3,817,814 shares of the company's stock, valued at $20,578,017.46. Learn More on Shoshana Shendelman's trading history.

Who are Applied Therapeutics' active insiders?

Applied Therapeutics' insider roster includes Riccardo Perfetti (Insider), Shoshana Shendelman (CEO), and Charles Silberstein (CFO). Learn More on Applied Therapeutics' active insiders.

Are insiders buying or selling shares of Applied Therapeutics?

During the last twelve months, Applied Therapeutics insiders bought shares 1 times. They purchased a total of 30,000 shares worth more than $65,400.00. During the last twelve months, insiders at the sold shares 9 times. They sold a total of 849,027 shares worth more than $3,436,223.39. The most recent insider tranaction occured on March, 14th when CEO Shoshana Shendelman sold 318,573 shares worth more than $1,717,108.47. Insiders at Applied Therapeutics own 19.1% of the company. Learn More about insider trades at Applied Therapeutics.

Information on this page was last updated on 3/14/2024.

Shoshana Shendelman Insider Trading History at Applied Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/14/2024Sell318,573$5.39$1,717,108.473,817,814View SEC Filing Icon  
11/30/2023Sell3,968$1.97$7,816.962,596,387View SEC Filing Icon  
9/27/2023Sell115,632$2.70$312,206.402,600,355View SEC Filing Icon  
1/11/2023Sell15,870$0.91$14,441.70751,625View SEC Filing Icon  
10/14/2022Buy50,000$0.65$32,500.00767,495View SEC Filing Icon  
10/12/2022Buy38,153$0.52$19,839.56644,239View SEC Filing Icon  
9/13/2021Buy701$14.69$10,297.69354,986View SEC Filing Icon  
7/21/2020Sell15,000$27.06$405,900.00569,285View SEC Filing Icon  
7/9/2020Sell15,000$31.10$466,500.00569,285View SEC Filing Icon  
7/7/2020Sell15,000$32.17$482,550.00569,285View SEC Filing Icon  
5/28/2020Sell125,000$42.70$5,337,500.003,014,005View SEC Filing Icon  
5/16/2019Buy125,000$10.00$1,250,000.00View SEC Filing Icon  
See Full Table

Shoshana Shendelman Buying and Selling Activity at Applied Therapeutics

This chart shows Shoshana Shendelman's buying and selling at Applied Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Applied Therapeutics Company Overview

Applied Therapeutics logo
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.
Read More

Today's Range

Now: $4.38
Low: $4.36
High: $4.89

50 Day Range

MA: $5.78
Low: $2.68
High: $7.40

2 Week Range

Now: $4.38
Low: $0.93
High: $9.39

Volume

2,888,305 shs

Average Volume

1,988,142 shs

Market Capitalization

$463.80 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.81
Secret Bull Market Starts in This Unusual Sector
From Altimetry   |   Ad
"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.
Click for my No. 1 investment, all free of charge, click here.